Dexamethasone (Synonyms: 地塞米松; Hexadecadrol; Prednisolone F)

目录号: HY-14648 纯度: 99.86%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Dexamethasone (Hexadecadrol) 是糖皮质激素受体 (glucocorticoid receptor) 激动剂、凋亡诱导剂，和常见的实验动物的疾病诱导剂，可构建肌肉萎缩、高血压和抑郁模型。Dexamethasone 可抑制巨噬细胞中炎性 miRNA-155 外泌体的产生，显著降低中性粒细胞以及单核细胞的炎症因子表达。Dexamethasone 还有潜力用于 COVID-19 的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dexamethasone Chemical Structure

CAS No. : 50-02-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥350	In-stock
500 mg	￥500	In-stock
1 g	￥837	In-stock
5 g	￥2046	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Dexamethasone:

Dexamethasone acetate In-stock
Dexamethasone (Water Soluble) In-stock
Dexamethasone-d₅ In-stock
Dexamethasone-4,6α,21,21-d₄ In-stock
Dexamethasone-d₃-1 In-stock
Dexamethasone phosphate disodium In-stock
Dexamethasone acetate hydrate 询价
Dexamethasone-d₅-1 询价
Dexamethasone-d₄ 询价
Dexamethasone phosphate 询价
Dexamethasone (GMP) 询价
Dexamethasone (Standard) 询价

MCE 顾客使用本产品发表的 162 篇科研文献

Proliferation Assay

RT-PCR

: Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.; Western blotting analysis of Itgb2 levels in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

: Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.; mRNA levels of Itgb2 in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

: Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.; Immunofluorescence analysis of Itgb2 in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

: Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030. [Abstract]; qRT‐PCR results show that DEX (DEX; 25 μg/g ; once a day; for 10 days)-induced myotube atrophy can increase the expression levels of MuRF1, Atrogin‐1, FoxO3a, SYISL, and miR‐205‐5p, decrease the expression levels of miR‐23a‐3p and miR‐103‐3p, but does not affect the expression level of SYNPO2.

: Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030. [Abstract]; Representative photographs of H&E and Lamin immunofluorescence staining for WT and KO TA muscles. Quantification of five independent experiments shows that knockout of SYISL alleviates muscle weight loss caused by Dexamethasone (DEX; 25 μg/g ; once a day; for 10 days)-induced muscle atrophy.

: Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030. [Abstract]; Western blotting results show that SYISL overexpression can further promote protein ubiquitination levels in Dexamethasone (DEX; 25 μg/g ; once a day; for 10 days)-induced muscular atrophy. Muscle atrophy is induced by intraperitoneal injection of DEX for 10 days in 3‐month‐old wild‐type and KO mice, respectively.

: Dexamethasone purchased from MCE. Usage Cited in: Br J Pharmacol. 2021 Aug;178(15):2976-2997. [Abstract]; Primary microglial cells incubated with Protopanaxadiol (100 μM), Dexamethasone (100 nM) or Dexamethasone-BSA (10 nM) show remarkable dynorphin A expression. Pretreatment with Dexamethasone-21-mesylate for 0.5 h completely abolished Protopanaxadiol-, Dexamethasone- or Dexamethasone-BSA-stimulated dynorphin A expression.

: Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378. [Abstract]; The migration assay of 4T1 cells in different condition. 4T1 cells were pretreated with 100 nM Dexamethasone (Dex) for 48 h and then are used for Transwell.

: Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378. [Abstract]; 4T1 cells are treated with Dexamethasone (Dex; 100 nM)/GSK650394 in vitro for 48 h before inoculation via intravenous injection.

: Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378. [Abstract]; The GR expression of 4T1 cells treated with Dexamethasone (100 nM)/Mifepristone for 48 h.

: Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378. [Abstract]; For in situ treatment in the 4T1 tumor model, Dexamethasone (Dex; 3 mg/kg) is performed every three days by gavage twice/day. The expression of Nedd4l, p-Nedd4l, Smad2 and p-Smad2 after SGK1 knockout.

: Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730. [Abstract]; Western blot analysis of iRhom2, TNF-α, and BAFF expression in Raw264.7 cells treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h.

: Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730. [Abstract]; Raw264.7 cells are treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h, mRNA level of iRhom2 in Raw264.7 cells is detected by quantitative real-time PCR. Data are presented by the relative amount of mRNA normalized by GAPDH.

: Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730. [Abstract]; Raw264.7 cells are treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h, the optical density values at 450 nm were measured and the cell viability was determined by CCK-8 assay.

: Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730. [Abstract]; Raw264.7 macrophages induced with LPS (1 μg/mL) for 6 h. Then cellular uptake of Cy5-labeled Dexamethasone (Dex)/OxiαCD NPs or Dex/FA-Oxi-αCD NPs is assessed using confocal laser scanning microscopy at various times.

: Dexamethasone purchased from MCE. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145. [Abstract]; Translocation of FoxO3 after treatment with S-Rg3 in DEX-treated C2C12 myotubes was investigated by immunofluorescence staining.

: Dexamethasone purchased from MCE. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145. [Abstract]; After C2C12 myotubes are incubated with Dexamethasone (DEX) and S-Rg3 for 24 h, myotube levels of MuRF1 and atrogin-1 are detected using Western blot analysis.

Dexamethasone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

查看 ADC Cytotoxin 亚型特异性产品:

查看所有亚型

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research^[1]^[2]^[3]^[4].

IC₅₀ & Target

Glucocorticoid receptor^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 15 μM Compound: Dex	Anticancer against human A549 cells after 72 hrs by MTT assay Anticancer against human A549 cells after 72 hrs by MTT assay	[PMID: 24992071]
A549	EC₅₀	1 nM Compound: Dexamethasone	Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay	[PMID: 16643060]
A549	EC₅₀	1.1 nM Compound: Dexamethasone	Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay	[PMID: 20047280]
A549	EC₅₀	1.1 nM Compound: 1, Dex	Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay	[PMID: 24980053]
A549	EC₅₀	1.1 nM Compound: 1, Dex	Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay	[PMID: 23953070]
A549	EC₅₀	1.1 nM Compound: Dex	Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay	[PMID: 23916594]
A549	EC₅₀	1.1 nM Compound: 1, dex	Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay	[PMID: 21073190]
A549	EC₅₀	1.1 nM Compound: dex	Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay	[PMID: 19321341]
A549	EC₅₀	2.5 nM Compound: Dexamethasone	Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay	[PMID: 20047280]
A549	EC₅₀	2.5 nM Compound: 1, Dex	Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay	[PMID: 24980053]
A549	EC₅₀	2.5 nM Compound: Dexamethasone	Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay	[PMID: 24011644]
A549	EC₅₀	2.5 nM Compound: 1, Dex	Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay	[PMID: 23953070]
A549	EC₅₀	2.5 nM Compound: Dex	Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay	[PMID: 23916594]
A549	EC₅₀	2.5 nM Compound: 1, dex	Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay	[PMID: 21073190]
B16-F10	IC₅₀	> 20 μM Compound: Dex	Anticancer against mouse B16F10 cells after 72 hrs by MTT assay Anticancer against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 24992071]
B-cell	IC₅₀	0.8 μM Compound: Dexamethasone	Immunosuppressive activity against BALB/C mouse B lymphocytes assessed as reduction in LPS-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method Immunosuppressive activity against BALB/C mouse B lymphocytes assessed as reduction in LPS-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method	[PMID: 31961677]
BV-2	IC₅₀	2.5 x 10^-2 μM Compound: Dexamethasone	Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26110443]
CHO	IC₅₀	> 20 μM Compound: Dex	Cytotoxicity against CHO cells after 72 hrs by MTT assay Cytotoxicity against CHO cells after 72 hrs by MTT assay	[PMID: 24992071]
COS-7	EC₅₀	7.2 nM Compound: Dexamethasone	Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay	[PMID: 19863083]
CV-1	ED₅₀	0.1 nM Compound: dexamethasone	Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay	[PMID: 18032610]
CV-1	EC₅₀	0.2 nM Compound: dexamethasone	Agonist activity at human GR expressed in CV1 cells by GRE activation assay Agonist activity at human GR expressed in CV1 cells by GRE activation assay	[PMID: 17705362]
Fibroblast	IC₅₀	> 15 μM Compound: Dex	Cytotoxicity against mouse fibroblasts after 72 hrs by MTT assay Cytotoxicity against mouse fibroblasts after 72 hrs by MTT assay	[PMID: 24992071]
HEK293	IC₅₀	> 500 μM Compound: dexamethasone	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	EC₅₀	1.3 nM Compound: DEX	Agonist activity at human GCR expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human GCR expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HEK-293T	IC₅₀	> 20 μM Compound: Dex	Cytotoxicity against HEK293T cells after 72 hrs by MTT assay Cytotoxicity against HEK293T cells after 72 hrs by MTT assay	[PMID: 24992071]
HeLa	EC₅₀	17 nM Compound: 1a	Activation of MMTV in HeLa cells measured by luciferase activity Activation of MMTV in HeLa cells measured by luciferase activity	[PMID: 17181172]
HeLa	EC₅₀	17 nM Compound: Dexamethasone	Transactivation of glucocorticoid receptor in human HeLa cells harboring MMTV promoter by luciferase reporter gene assay Transactivation of glucocorticoid receptor in human HeLa cells harboring MMTV promoter by luciferase reporter gene assay	[PMID: 24656565]
HeLa	EC₅₀	4.2 nM Compound: Dexamethasone	Transactivation of GR-LBD expressed in human HeLa cells co-expressing GAL4-DBD by luciferase reporter gene assay Transactivation of GR-LBD expressed in human HeLa cells co-expressing GAL4-DBD by luciferase reporter gene assay	[PMID: 24011644]
HeLa	EC₅₀	4.2 nM Compound: 1, dex	Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay	[PMID: 21073190]
HeLa	EC₅₀	4.5 nM Compound: 1, Dex	Agonist activity at glucocorticoid receptor in human HeLa cells assessed as NP-1 transactivation by luciferase reporter gene assay Agonist activity at glucocorticoid receptor in human HeLa cells assessed as NP-1 transactivation by luciferase reporter gene assay	[PMID: 24980053]
HeLa	EC₅₀	4.5 nM Compound: 1, Dex	Transactivation of glucocorticoid receptor ligand binding domain (unknown origin) transfected in human HeLa cells assessed as activation of NP-1 by GAL4 luciferase reporter gene assay Transactivation of glucocorticoid receptor ligand binding domain (unknown origin) transfected in human HeLa cells assessed as activation of NP-1 by GAL4 luciferase reporter gene assay	[PMID: 23953070]
HeLa	EC₅₀	4.5 nM Compound: Dex	Transactivation activity at glucocorticoid receptor ligand binding domain (unknown origin) expressed in human Hela cells co-expressing GAL4 DNA binding domain assessed as NP-1-stimulated GRE activation by luciferase reporter gene assay Transactivation activity at glucocorticoid receptor ligand binding domain (unknown origin) expressed in human Hela cells co-expressing GAL4 DNA binding domain assessed as NP-1-stimulated GRE activation by luciferase reporter gene assay	[PMID: 23916594]
HeLa	EC₅₀	4.5 nM Compound: Dexamethasone	Transactivation of GAL-4 tagged glucocorticoid receptor ligand binding domain expressed in human HeLa cells assessed as NP1 activation by luciferase reporter gene assay Transactivation of GAL-4 tagged glucocorticoid receptor ligand binding domain expressed in human HeLa cells assessed as NP1 activation by luciferase reporter gene assay	[PMID: 20047280]
HeLa S3	IC₅₀	4.1 nM Compound: dexamethasone	Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells after 2 hrs Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells after 2 hrs	[PMID: 23403082]
HepG2	EC₅₀	2.6 μM Compound: Dexamethasone	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HFF	EC₅₀	0.5 nM Compound: dexamethasone	Antiinflammatory activity assessed as inhibition of IL1 stimulated IL6 production in HFF cells by transrepression assay Antiinflammatory activity assessed as inhibition of IL1 stimulated IL6 production in HFF cells by transrepression assay	[PMID: 17692519]
HFF	EC₅₀	1.9 nM Compound: 1a	Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay	[PMID: 17181172]
HFF	EC₅₀	2 nM Compound: dexamethasone	Antiinflammatory activity assessed as upregulation of aromatase in HFF cells by transactivation assay Antiinflammatory activity assessed as upregulation of aromatase in HFF cells by transactivation assay	[PMID: 17692519]
Huh-7	EC₅₀	5 nM Compound: 1, dex	Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs	[PMID: 21073190]
J774	IC₅₀	5.2 μM Compound: Dexamethasone	Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS/IFNgamma-induced NO production incubated for 24 hrs by Griess method Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS/IFNgamma-induced NO production incubated for 24 hrs by Griess method	[PMID: 32364737]
J774	CC₅₀	91.1 μM Compound: Dexa	Cytotoxicity against BALB/c mouse J774 cells assessed as reduction in cell viability after 72 hrs by alamarBlue assay Cytotoxicity against BALB/c mouse J774 cells assessed as reduction in cell viability after 72 hrs by alamarBlue assay	[PMID: 29523468]
J774.1	IC₅₀	170 μM Compound: dexamethasone	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs	[PMID: 12608860]
J774.A1	IC₅₀	0.165 μg/mL Compound: Dexamethasone	Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
J774.A1	IC₅₀	0.4 μM Compound: DEXA	Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay	[PMID: 25824662]
J774.A1	IC₅₀	22 μM Compound: DEXA	Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay	[PMID: 25824662]
J774.A1	IC₅₀	9.09 μg/mL Compound: Dexamethasone	Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
L02	IC₅₀	4620.58 μM Compound: Dex	Antiinflammatory activity against human L02 assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess assay relative to control Antiinflammatory activity against human L02 assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess assay relative to control	[PMID: 33515864]
L02	IC₅₀	4620.58 μM Compound: Dex	Cytotoxicity against human L02 cells cells assessed as cell viability by MTT assay Cytotoxicity against human L02 cells cells assessed as cell viability by MTT assay	[PMID: 33515864]
LLC-PK1	IC₅₀	> 50 μM Compound: Dexamethasone	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Dexamethasone	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Dexamethasone	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
Macrophage	IC₅₀	0.134 μM Compound: Dexamethasone	Inhibition of TNFalpha expression in LPS-induced macrophages (unknown origin) incubated for 24 hrs by ELISA Inhibition of TNFalpha expression in LPS-induced macrophages (unknown origin) incubated for 24 hrs by ELISA	[PMID: 31473042]
MCF7	IC₅₀	> 15 μM Compound: Dex	Anticancer against human MCF7 cells after 72 hrs by MTT assay Anticancer against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24992071]
Multiple myeloma cancer stem cell	IC₅₀	> 100000 nM Compound: DEX	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
PBMC	EC₅₀	> 0.2 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MCP-1 production after 24 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MCP-1 production after 24 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.00047 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced GM-CSF production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced GM-CSF production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.00092 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-4 production after 24 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-4 production after 24 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.001 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-5 production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-5 production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0012 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-13 production after 24 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-13 production after 24 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0019 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced TNFalpha production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced TNFalpha production after 48 hrs	[PMID: 23199485]
PBMC	IC₅₀	0.002 μM Compound: dexamethasone	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	EC₅₀	0.0021 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-1beta production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-1beta production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0024 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IP-10 production after 24 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IP-10 production after 24 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0035 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-3 production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-3 production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0036 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-2 production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-2 production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0041 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-12p70 production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-12p70 production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0055 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-10 production after 48 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-10 production after 48 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0061 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced TNFalpha production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced TNFalpha production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.0076 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IFNgamma production after 24 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IFNgamma production after 24 hrs	[PMID: 23199485]
PBMC	IC₅₀	0.008 μM Compound: dexamethasone	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	0.009 μM Compound: dexamethasone	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	EC₅₀	0.0094 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-1beta production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-1beta production after 6 hrs	[PMID: 23199485]
PBMC	IC₅₀	0.0095 μM Compound: Dexamethasone	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	[PMID: 23411072]
PBMC	EC₅₀	0.01 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.014 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 6 hrs	[PMID: 23199485]
PBMC	IC₅₀	0.017 μM Compound: Dexamethasone	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	[PMID: 23411072]
PBMC	EC₅₀	0.055 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.066 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced MIP1alpha production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced MIP1alpha production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.072 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.082 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-6 production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-6 production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.088 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-8 production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-8 production after 6 hrs	[PMID: 23199485]
PBMC	EC₅₀	0.13 μM Compound: 1	Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MIP1alpha production after 6 hrs Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MIP1alpha production after 6 hrs	[PMID: 23199485]
PBMC	IC₅₀	3.6 nM Compound: Dexamethasone	Inhibition of TNF-alpha production in LPS-stimulated human PBMC measured after 24 hrs by ELISA Inhibition of TNF-alpha production in LPS-stimulated human PBMC measured after 24 hrs by ELISA	[PMID: 35870364]
Peritoneal macrophage	IC₅₀	0.15 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse peritoneal macrophages assessed as inhibition of LPS-induced NO production incubated for 22 hrs by Griess reagent based colorimetric assay Anti-inflammatory activity in mouse peritoneal macrophages assessed as inhibition of LPS-induced NO production incubated for 22 hrs by Griess reagent based colorimetric assay	[PMID: 31358465]
R1	IC₅₀	5 nM Compound: Dexamethasone	Inhibition of glucocorticoid receptor-glucocorticoid complex transfected in rat R1 cells assessed as down-regulation of TPA-responsive element proinflammatory gene expression at 10 uM after 24 hrs by beta-galactosidase assay Inhibition of glucocorticoid receptor-glucocorticoid complex transfected in rat R1 cells assessed as down-regulation of TPA-responsive element proinflammatory gene expression at 10 uM after 24 hrs by beta-galactosidase assay	[PMID: 18412397]
RAW	IC₅₀	20 nM Compound: DXM	Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs	[PMID: 17367124]
RAW264.7	IC₅₀	> 25 μg/mL Compound: Dexamethasone	Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay	[PMID: 15165136]
RAW264.7	CC₅₀	> 50 μM Compound: Dexamethasone	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 30528697]
RAW264.7	IC₅₀	> 50 μM Compound: Dex	Cytotoxicity against LPS-induced mouse RAW 264.7 cells assessed as cell viability measured by MTT assay Cytotoxicity against LPS-induced mouse RAW 264.7 cells assessed as cell viability measured by MTT assay	[PMID: 33515864]
RAW264.7	IC₅₀	> 50 μM Compound: Dex	Cytotoxicity against mouse RAW 264.7 cells assessed as cell viability by MTT assay Cytotoxicity against mouse RAW 264.7 cells assessed as cell viability by MTT assay	[PMID: 33515864]
RAW264.7	IC₅₀	0.01 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay	[PMID: 31301930]
RAW264.7	IC₅₀	0.01 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 30931559]
RAW264.7	IC₅₀	0.01 μM Compound: Dexsamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
RAW264.7	IC₅₀	0.016 μg/mL Compound: Dexamethasone	Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
RAW264.7	IC₅₀	0.04 μM Compound: DEXA	Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay	[PMID: 25824662]
RAW264.7	IC₅₀	0.13 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay	[PMID: 30808589]
RAW264.7	IC₅₀	0.47 μM Compound: Hexadecadrol	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method	[PMID: 22372956]
RAW264.7	IC₅₀	0.58 μM Compound: Dex	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 34333975]
RAW264.7	IC₅₀	0.62 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs	[PMID: 32485533]
RAW264.7	IC₅₀	0.63 μM Compound: dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26087384]
RAW264.7	IC₅₀	0.63 μM Compound: DXM	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs in presence of LPS by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs in presence of LPS by Griess assay	[PMID: 27825545]
RAW264.7	IC₅₀	0.7 μM Compound: dexamethasone	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on TNFalpha formation pretreated 1 hr before LPS challenge measured after 24 hrs Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on TNFalpha formation pretreated 1 hr before LPS challenge measured after 24 hrs	[PMID: 11908984]
RAW264.7	IC₅₀	0.8 μM Compound: dexamethasone	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 26305406]
RAW264.7	IC₅₀	0.8 μM Compound: Dexamethasone	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay relative to vehicle-treated control Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay relative to vehicle-treated control	[PMID: 25499882]
RAW264.7	IC₅₀	0.8 μM Compound: Dexsamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
RAW264.7	IC₅₀	0.8 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by griess assay	[PMID: 29272126]
RAW264.7	IC₅₀	0.86 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 2 hrs before LPS challenge measured after 18 hrs by griess reaction Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 2 hrs before LPS challenge measured after 18 hrs by griess reaction	[PMID: 21288727]
RAW264.7	IC₅₀	0.98 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method	[PMID: 22537362]
RAW264.7	IC₅₀	1.2 μM Compound: DEX	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA	[PMID: 30579802]
RAW264.7	IC₅₀	1.43 μM Compound: dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method	[PMID: 23373965]
RAW264.7	IC₅₀	1.84 μg/mL Compound: Dexamethasone	Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
RAW264.7	IC₅₀	10.7 μM Compound: Dexamethasone	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 29518326]
RAW264.7	IC₅₀	14.75 μM Compound: Dexamethasone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay	[PMID: 33933753]
RAW264.7	IC₅₀	159.2 μM Compound: Dexamethasone	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay	[PMID: 31260892]
RAW264.7	IC₅₀	159.2 μM Compound: Dexamethasone	Cytotoxicity against mouse RAW264.7 by WST-1 vital dye reagent method Cytotoxicity against mouse RAW264.7 by WST-1 vital dye reagent method	[PMID: 35567964]
RAW264.7	IC₅₀	18.4 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 12 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 12 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 31181925]
RAW264.7	IC₅₀	2.5 μM Compound: Dexamethasone	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 28598633]
RAW264.7	IC₅₀	2.66 μM Compound: Dex	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 30108912]
RAW264.7	IC₅₀	20 nM Compound: DXM	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction	[PMID: 21361338]
RAW264.7	IC₅₀	22.2 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess reagent assay Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess reagent assay	[PMID: 35007071]
RAW264.7	IC₅₀	24.3 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS addition and measured after 18 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS addition and measured after 18 hrs by Griess reagent-based assay	[PMID: 32935986]
RAW264.7	IC₅₀	32.5 μM Compound: DXMS	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 32070636]
RAW264.7	IC₅₀	355.14 μM Compound: dexamethasone	Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method	10.1007/s00044-013-0504-9
RAW264.7	IC₅₀	36 μg/mL Compound: Dexamethasone	Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs	[PMID: 15165136]
RAW264.7	CC₅₀	4.4 μM Compound: Dexamethasone	Cytotoxicity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based colorimetric assay Cytotoxicity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based colorimetric assay	[PMID: 35998343]
RAW264.7	IC₅₀	4.7 μM Compound: DEXA	Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay	[PMID: 25824662]
RAW264.7	IC₅₀	5.02 μM Compound: Dexamethasone	Inhibition of NO release in mouse RAW264.7 incubated for 15 mins by fluoroscence-luminescence reader infinite M200 Pro analysis Inhibition of NO release in mouse RAW264.7 incubated for 15 mins by fluoroscence-luminescence reader infinite M200 Pro analysis	[PMID: 35567964]
RAW264.7	IC₅₀	5.02 μM Compound: Dexamethasone	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome	[PMID: 31260892]
RAW264.7	IC₅₀	6 μM Compound: Dexamethasone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent-based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent-based assay	[PMID: 31577434]
RAW264.7	IC₅₀	6.1 μM Compound: Dexamethasone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 24 hrs by ELISA	[PMID: 31577434]
RAW264.7	IC₅₀	6.9 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs in presence of LPS by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs in presence of LPS by Griess reagent-based assay	[PMID: 33914536]
RAW264.7	IC₅₀	7 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 28499733]
RAW264.7	IC₅₀	7.9 μM Compound: Dexamethasone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 35063896]
RAW264.7	IC₅₀	7.9 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 30817151]
RAW264.7	IC₅₀	7.9 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 3 hrs followed by LPS addition and measured after 24 hrs Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 3 hrs followed by LPS addition and measured after 24 hrs	[PMID: 37002536]
RAW264.7	IC₅₀	8.28 μM Compound: Dexamethasone	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent-based assay	[PMID: 33667092]
RAW264.7	IC₅₀	8.4 μM Compound: Dexamethasone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 secretion after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 secretion after 24 hrs by ELISA	[PMID: 31577434]
RAW264.7	IC₅₀	8.7 μM Compound: Dexamethasone	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production pretreated for 30 mins followed by LPS stimulation for 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production pretreated for 30 mins followed by LPS stimulation for 24 hrs by ELISA	[PMID: 30528697]
RAW264.7	IC₅₀	8.71 μM Compound: Dex	Inhibition of LPS-induced NO release in mouse RAW264.7 cells preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO release in mouse RAW264.7 cells preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 33515864]
RAW264.7	IC₅₀	9.4 μM Compound: DEX	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA	[PMID: 30579802]
REH	EC₅₀	6.7 nM Compound: Dexamethasone	Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay	[PMID: 34046609]
RPMI-8226	IC₅₀	6.5 nM Compound: dexamethasone	Antiproliferative activity against human RPMI8226 cells after 4 days Antiproliferative activity against human RPMI8226 cells after 4 days	[PMID: 17705362]
Splenocyte	IC₅₀	0.001 μM Compound: Dexa	Immunomodulatory activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced lymphocyte proliferation by measuring [3H]-thymidine uptake after 48 to 72 hrs by scintillation counting analysis Immunomodulatory activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced lymphocyte proliferation by measuring [3H]-thymidine uptake after 48 to 72 hrs by scintillation counting analysis	[PMID: 29523468]
SW1353	IC₅₀	1.8 nM Compound: DEX	Transrepression activity at glucocorticoid receptor in human SW1353 cells assessed as repression of IL-1-induced MMP-13 production after 24 hrs by ELISA Transrepression activity at glucocorticoid receptor in human SW1353 cells assessed as repression of IL-1-induced MMP-13 production after 24 hrs by ELISA	[PMID: 25706100]
T-cell	IC₅₀	0.005 μM Compound: Dexamethasone	Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells	[PMID: 11229767]
T-cell	IC₅₀	1.6 μM Compound: Dexamethasone	Immunosuppressive activity against BALB/C mouse T lymphocytes assessed as reduction in concanavalin A-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method Immunosuppressive activity against BALB/C mouse T lymphocytes assessed as reduction in concanavalin A-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method	[PMID: 31961677]
THP-1	IC₅₀	0.007 μM Compound: dexamethasone	Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 by ELISA	[PMID: 18625560]
THP-1	IC₅₀	0.05 μM Compound: dexamethasone	Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha by ELISA	[PMID: 18625560]

体外研究
(In Vitro)

Dexamethasone (Hexadecadrol) 调节多种转录因子，包括激活蛋白-1、核因子-AT 和核因子-kB，从而激活和抑制参与炎症反应的关键基因^[1]。
Dexamethasone 有效抑制 A549 细胞释放粒细胞-巨噬细胞集落刺激因子 (GM-CSF)，EC₅₀ 为 2.2 nM。Dexamethasone (EC₅₀=36 nM) 诱导 β₂ 受体的转录被发现与糖皮质激素受体 (GR) DNA 结合相关，发生率高 10-100 倍浓度高于抑制 GM-CSF 释放。Dexamethasone (IC₅₀=0.5 nM) 抑制 3×κB (NF-κB、IκBα 和 I-κBβ)，这与抑制 GM-CSF 释放有关^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

根据 Dexamethasone (DEX) 的血液和多组织浓度-时间曲线，发现其组织分布没有重大性别差异。血细胞与血浆分配 (0.664) 和血浆游离分数 (0.175) 中等，广泛分布在肝脏中 (Kp=6.76)。可能是由于 P-糖蛋白介导的外流，与预期的高渗透性相比，大脑中 DEX 的浓度非常低^[5]。
Dexamethasone (DEX) 可用于动物建模，构建肌肉萎缩、高血压和抑郁模型。

1. 诱导肌肉萎缩^[6]^[7]

致病原理

糖皮质激素是骨骼肌蛋白降解和上调泛素蛋白酶体途径的重要介质。Dexamethasone 通过结合糖皮质激素受体诱导胫骨前肌蛋白降解，导致肌肉萎缩。

具体造模方法：

Mice: C57BL/6 • male • 6-week-old
Administration: 5 mg/kg • ip • once daily for 2 weeks

造模成功指标

分子变化：指标增加项--C₂C₁₂ 泛素连接酶、MuRF1、Atrogin-1、Cbl-b、p-Foxo1、p-Foxo3a。其他--导致 C 肌管蛋白降解。糖皮质激素受体易位至细胞核。

表型观测：前肌、腓肠肌、股四头肌和比目鱼肌测重减少。骨骼肌与体重的比值下降。

同类产品 Betamethasone (HY-13570)

拮抗产品 Glabridin (HY-N0393)

2. 诱导高血压^[8]^[9]

致病原理

诱发高血压 (HT) 的潜在机制尚不清楚。

具体造模方法：

Rat: Sprague-Dawley • Male • 200-300 g
Administration: 20 μg • sc • once daily from days 5 to 16 • control rats: saline with 0.1 mL/100 g/day from days 1 to 16 (po) or 0.2 mL/rat/day (sc).

Dog: 10.1-19.1 kg • average=13.7 kg
Administration: 0.5 mg/kg • po • once daily for 10 days

造模成功指标

血流动力学：中枢血流动力学中 MAP、收缩压、舒张压、TPR 水平升高。总外周阻力、血压、心房钠尿肽以及对去甲肾上腺素的升压反应在全身和肾脏血流动力学中显着增加。

行为观测：犬表现出明显的排钠利尿作用。

拮抗产品 Saralasin (HY-P0205); Prazosin (HY-B0193)

3. 诱导抑郁行为^[10]^[11]

致病原理

星形胶质细胞是重度抑郁症 (MD) 的一个关键特征，糖皮质激素表达减少会导致星形胶质细胞数量减少。长期使用 Dexamethasone 处理会导致啮齿类动物出现一系列类似抑郁症的症状。

具体造模方法：

Rat: Sprague-Dawley • Male • 200-250 g
Administration: 1 mg/kg • po • once daily every other day for 5 months

Note

(1) 制备 3% (w/v) 处理溶液，并通过 0.45 μm 醋酸纤维素过滤器过滤。
(2) 开始处理前 4 天，老鼠不应该接触除此之外的任何其他水源。
(3) 第 4 天，将处理液换成水，喂食 3 天，使小鼠暂时恢复。第 7 天称重并进行行为实验。

Mice: C57BL/6 • Male • 9-10 weeks old • 23-25 g
Administration: 4 mg/kg • ip • once dailly for 21 days

造模成功指标

代谢变化：大鼠血清皮质醇水平 ↑。

行为观测：强迫游泳测试（FST）期间的不动时间 ↑。蔗糖偏好测试中对蔗糖的偏好 ↓。

拮抗产品 Amitriptyline (HY-B0527)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

392.46

Formula

C₂₂H₂₉FO₅

CAS 号

50-02-2

性状

固体

颜色

White to off-white

中文名称

地塞米松

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (254.80 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 8.33 mg/mL (21.23 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5480 mL	12.7402 mL	25.4803 mL
5 mM	0.5096 mL	2.5480 mL	5.0961 mL
10 mM	0.2548 mL	1.2740 mL	2.5480 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液
方案二

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.30 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案三

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.30 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案四

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.30 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 18.18 mg/mL (46.32 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.86%

选择批次：

Data Sheet (698 KB) SDS (420 KB)

COA (292 KB) LCMS (121 KB) 元素分析报告 (215 KB)

产品使用指南 (1538 KB)

参考文献

[1]. LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. [Content Brief]

[2]. Adcock IM, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11 [Content Brief]

[3]. Ballabh P, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83. [Content Brief]

[4]. Yun Chen, et al. Glucocorticoids inhibit production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. Int J Clin Exp Pathol 2018;11(7):3391-3397.

[5]. Song D, et al. Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metab Dispos. 2020 Sep;48(9):811-818. [Content Brief]

[6]. Yoshioka Y, et al. Glabridin inhibits dexamethasone-induced muscle atrophy. Arch Biochem Biophys. 2019 Mar 30;664:157-166. [Content Brief]

[7]. Troncoso R, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13(14):2281-95. [Content Brief]

[8]. Ong SL, et al. Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res. 2009 Oct;32(10):889-94. [Content Brief]

[9]. Nakamoto H, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A. 1991;13(4):587-606. [Content Brief]

[10]. Mesripour A, et al. The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair. Nutr Neurosci. 2019 Oct;22(10):744-749. [Content Brief]

[11]. Bhatt S, et al. Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. Basic Clin Pharmacol Toxicol. 2016 Jul;119(1):10-8. [Content Brief]

Animal Administration ^[3]^[4]	Mice^[3] Female C57Bl/6JBom mice (age 10-12 weeks) are used in all experiments. Dexamethasone is administered as a single injection of 1 or 10 mg/kg. Dexamethasone is dissolved in saline and 400 μL are injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, N-acetylcysteine (NAC) (100 and 500 mg/kg) is injected successively every 4•5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals are injected intraperitoneally with solvent alone (saline). Intratracheal administration is performed by instillation of 100 μL NAC (50, 100 or 500 mg/kg) or Dexamethasone (10 mg/kg) into the lungs of mice. Rats^[4] Male Sprague-Dawley rats are used.Dexamethasone-treated rats are injected intraperitoneally once daily with Dexamethasone (1.5 mg/kg body weight) for 5 days and are allowed to feed ad libitum. The Dexamethasone dose (1.5 mg/kg/day) and the duration of treatment (5 days) are specifically chosen as this treatment induced a reproducible and marked catabolic state. Control rats received no treatment and are fed ad libitum. In order to take into account the decrease in food intake induced by Dexamethasone treatment, a third group of pair-fed rats are used. These rats are provided with the same amount of food as Dexamethasone-injected rats and are treated with a daily isovolumic intraperitoneal injection of NaCl (0.9%) for 5 days. After the final injection of Dexamethasone or NaCl, the animals are fasted overnight prior to being killed by decapitation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. [Content Brief] [2]. Adcock IM, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11 [Content Brief] [3]. Ballabh P, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83. [Content Brief] [4]. Yun Chen, et al. Glucocorticoids inhibit production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. Int J Clin Exp Pathol 2018;11(7):3391-3397. [5]. Song D, et al. Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metab Dispos. 2020 Sep;48(9):811-818. [Content Brief] [6]. Yoshioka Y, et al. Glabridin inhibits dexamethasone-induced muscle atrophy. Arch Biochem Biophys. 2019 Mar 30;664:157-166. [Content Brief] [7]. Troncoso R, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13(14):2281-95. [Content Brief] [8]. Ong SL, et al. Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res. 2009 Oct;32(10):889-94. [Content Brief] [9]. Nakamoto H, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A. 1991;13(4):587-606. [Content Brief] [10]. Mesripour A, et al. The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair. Nutr Neurosci. 2019 Oct;22(10):744-749. [Content Brief] [11]. Bhatt S, et al. Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. Basic Clin Pharmacol Toxicol. 2016 Jul;119(1):10-8. [Content Brief]

Animal Administration
^[3]^[4]

Mice^[3]
Female C57Bl/6JBom mice (age 10-12 weeks) are used in all experiments. Dexamethasone is administered as a single injection of 1 or 10 mg/kg. Dexamethasone is dissolved in saline and 400 μL are injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, N-acetylcysteine (NAC) (100 and 500 mg/kg) is injected successively every 4•5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals are injected intraperitoneally with solvent alone (saline). Intratracheal administration is performed by instillation of 100 μL NAC (50, 100 or 500 mg/kg) or Dexamethasone (10 mg/kg) into the lungs of mice.
Rats^[4]
Male Sprague-Dawley rats are used.Dexamethasone-treated rats are injected intraperitoneally once daily with Dexamethasone (1.5 mg/kg body weight) for 5 days and are allowed to feed ad libitum. The Dexamethasone dose (1.5 mg/kg/day) and the duration of treatment (5 days) are specifically chosen as this treatment induced a reproducible and marked catabolic state. Control rats received no treatment and are fed ad libitum. In order to take into account the decrease in food intake induced by Dexamethasone treatment, a third group of pair-fed rats are used. These rats are provided with the same amount of food as Dexamethasone-injected rats and are treated with a daily isovolumic intraperitoneal injection of NaCl (0.9%) for 5 days. After the final injection of Dexamethasone or NaCl, the animals are fasted overnight prior to being killed by decapitation.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. [Content Brief]

[2]. Adcock IM, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11 [Content Brief]

[3]. Ballabh P, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83. [Content Brief]

[4]. Yun Chen, et al. Glucocorticoids inhibit production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. Int J Clin Exp Pathol 2018;11(7):3391-3397.

[5]. Song D, et al. Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metab Dispos. 2020 Sep;48(9):811-818. [Content Brief]

[6]. Yoshioka Y, et al. Glabridin inhibits dexamethasone-induced muscle atrophy. Arch Biochem Biophys. 2019 Mar 30;664:157-166. [Content Brief]

[7]. Troncoso R, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13(14):2281-95. [Content Brief]

[8]. Ong SL, et al. Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res. 2009 Oct;32(10):889-94. [Content Brief]

[9]. Nakamoto H, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A. 1991;13(4):587-606. [Content Brief]

[10]. Mesripour A, et al. The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair. Nutr Neurosci. 2019 Oct;22(10):744-749. [Content Brief]

[11]. Bhatt S, et al. Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. Basic Clin Pharmacol Toxicol. 2016 Jul;119(1):10-8. [Content Brief]

Dexamethasone 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.5480 mL	12.7402 mL	25.4803 mL	63.7008 mL
	5 mM	0.5096 mL	2.5480 mL	5.0961 mL	12.7402 mL
	10 mM	0.2548 mL	1.2740 mL	2.5480 mL	6.3701 mL
	15 mM	0.1699 mL	0.8493 mL	1.6987 mL	4.2467 mL
	20 mM	0.1274 mL	0.6370 mL	1.2740 mL	3.1850 mL
DMSO	25 mM	0.1019 mL	0.5096 mL	1.0192 mL	2.5480 mL
	30 mM	0.0849 mL	0.4247 mL	0.8493 mL	2.1234 mL
	40 mM	0.0637 mL	0.3185 mL	0.6370 mL	1.5925 mL
	50 mM	0.0510 mL	0.2548 mL	0.5096 mL	1.2740 mL
	60 mM	0.0425 mL	0.2123 mL	0.4247 mL	1.0617 mL
	80 mM	0.0319 mL	0.1593 mL	0.3185 mL	0.7963 mL
	100 mM	0.0255 mL	0.1274 mL	0.2548 mL	0.6370 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Dexamethasone (Synonyms: 地塞米松; Hexadecadrol; Prednisolone F)

Customer Review

Other Forms of Dexamethasone:

MCE 顾客使用本产品发表的 162 篇科研文献

Dexamethasone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 ADC Cytotoxin 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Dexamethasone 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Dexamethasone (Synonyms: 地塞米松; Hexadecadrol; Prednisolone F)

Customer Review

Other Forms of Dexamethasone:

Dexamethasone 相关抗体

MCE 顾客使用本产品发表的 162 篇科研文献

Dexamethasone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 ADC Cytotoxin 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Dexamethasone 相关抗体:

摩尔计算器

稀释计算器

Dexamethasone 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z